European Journal of Surgical Oncology
Volume 32, Issue 7 , Pages 719-724, September 2006

Clinical outcome and service implications of screening women at increased breast cancer risk from a family history

  • G.P.H. Gui

      Affiliations

    • Department of Academic Surgery and the Breast Diagnostic Unit, Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ, United Kingdom
    • Corresponding Author InformationCorresponding author. Tel.: +44 20 7808 2783; fax: +44 20 7808 2673.
  • ,
  • G. Kadayaprath

      Affiliations

    • Department of Academic Surgery and the Breast Diagnostic Unit, Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ, United Kingdom
  • ,
  • N. Darhouse

      Affiliations

    • Department of Academic Surgery and the Breast Diagnostic Unit, Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ, United Kingdom
  • ,
  • J. Self

      Affiliations

    • Department of Academic Surgery and the Breast Diagnostic Unit, Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ, United Kingdom
  • ,
  • A. Ward

      Affiliations

    • Department of Academic Surgery and the Breast Diagnostic Unit, Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ, United Kingdom
  • ,
  • R. A'Hern

      Affiliations

    • Department of Information Technology and Statistics, Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ, United Kingdom
  • ,
  • R. Eeles

      Affiliations

    • Translational Cancer Genetics Team, Institute of Cancer Research and Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ, United Kingdom

Accepted 3 May 2006.

Abstract 

Introduction

The value of special screening for women at moderate breast cancer risk with a family history of breast cancer remains controversial. Little is known about recall rates, false negative outcomes and the impact on clinical service. Despite this, surveillance programmes within breast units have been established in the United Kingdom.

Patients and methods

In our institution, screening of women at moderate (lifetime risk, 17–30%) and high risk (>30%) consisted of annual clinical examination and mammography from the age of 35 years. The active study period ran for four months and each patient was followed through a further screening cycle (whole study period), providing information on interval cancers and detection at the subsequent screen.

Results

One thousand one hundred and thirty-two women attended for their incident screen: 137 at high risk, 803 at moderate risk and 192 at standard risk. The median age at cancer diagnosis in the moderate risk group was 54 (range, 45–68) years and the high-risk group 51 (46–52) years, compared to 63 (45–69) years in the standard risk group. Seven cancers were diagnosed during the four-month active study period. Two patients were diagnosed with interval cancers and eight at the next screen, giving a cancer incidence in the whole study period of 17/1132 (1.5%). Thirteen patients had invasive cancer and four had ductal carcinoma in situ (DCIS) The median invasive tumour size was 15 had (range, 7–28)mm and the median DCIS size was 4 (2–30)mm. 10/13 (76.9%) invasive cancers were ≤20mm and 2/13 patients (15.4%) with invasive cancer were lymph node positive. The sensitivity and specificity of mammography were 85.7% and 98.8%, respectively. The mammogram recall rate was 27.6 per 1000. The benign to malignant surgery ratio was 8:17.

Conclusion

Screening women at increased breast cancer risk is effective. Early detection and recall rates are comparable to that of older women attending the British National Breast Screening Programme.

Keywords: Breast cancer risk, Breast screening, Family history, Breast cancer services

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This work was given as an oral presentation at the British Association of Surgical Oncology Scientific Meeting at the Royal College of Surgeons of England, 14–15 November 2005.

PII: S0748-7983(06)00210-1

doi:10.1016/j.ejso.2006.05.002

European Journal of Surgical Oncology
Volume 32, Issue 7 , Pages 719-724, September 2006